Henk Lokhorst1, Bronno van der Holt2*, Sonja Zweegman, MD, PhD3, Peter A. Von Dem Borne, MD, PhD4, Gerard M.J. Bos, MD, PhD5, Sandra Croockewit, MD, PhD6*, Jan J. Cornelissen, MD, PhD7, Marinus van Oers8*, Martyn Ronald Schaafsma9, Harm Sinnige, MD, PhD10*, Michel Delforge, MD, PhF11*, Okke de Weerdt12*, Pierre W Wijermans13, Shulamiet Wittebol, MD, PhD14*, Edo Vellenga, MD, PhD15*, Asiong Jie12*, Henriette Berenschot, MD, PhD16*, Marinus Marwijk-kooy, MD, PhD17* and Pieter Sonneveld, MD, PhD18
1Hematology, University Medical Center Utrecht, Utrecht, Netherlands
2Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
3Dept. of Hematology, 2pk BR018, VUMC, Amsterdam, Netherlands
4Stafcentrum Hematologie, C2-R, Leids University Medical Center,, Leiden, Netherlands
5Dept. of Internal Medicine, University Hospital Maastricht, Maastricht, Netherlands
6Haematology, University Medical Center St Radboud, Nijmegen, Netherlands
7Hematology, Erasmus MC/Daniel Den Hoed, Rotterdam, Netherlands
8AMC
9Medisch Spectrum Twente, Enschede, Netherlands
10Haematology 3/12, Jeroen Bosch Hospital, 's Hertogenbosch, Netherlands
11Myeloma Study Group, Belgian Hematological Socirty, Leuven, Belgium
12HOVON, Netherlands
13Hospital Leyenburg, The Hague, Netherlands
14Haematology, locatie Elisabeth, Meander Medical Center Amersfoort, Amersfoort
15Haematology, University Medical Center Groningen, Groningen, Netherlands
16Internal Medicine, Albert Schweitzer Hospital, location Dordwijk, Dordrecht, Netherlands
17Isala kliniek Zwolle
18Hematology, Erasmus Medical Center Rotterdam